| Literature DB >> 19643002 |
Ramaprabhu Vempati1, Ramesh Lal Bijlani, Kishore Kumar Deepak.
Abstract
BACKGROUND: There is a substantial body of evidence on the efficacy of yoga in the management of bronchial asthma. Many studies have reported, as the effects of yoga on bronchial asthma, significant improvements in pulmonary functions, quality of life and reduction in airway hyper-reactivity, frequency of attacks and medication use. In addition, a few studies have attempted to understand the effects of yoga on exercise-induced bronchoconstriction (EIB) or exercise tolerance capacity. However, none of these studies has investigated any immunological mechanisms by which yoga improves these variables in bronchial asthma.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19643002 PMCID: PMC2734746 DOI: 10.1186/1471-2466-9-37
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Demographics and Baseline Values of Outcome Variables
| Age, years (mean ± SD) | 33.5 ± 11.4 | 33.4 ± 11.5 | 0.96 |
| Males, n (%) | 13 (45) | 20 (71) | 0.29 |
| Females, n (%) | 16 (55) | 8 (29) | 0.19 |
| Weight, kg (mean ± SD) | 61.3 ± 11.5 | 58.9 ± 9.7 | 0.93 |
| Height, cm (mean ± SD) | 162 ± 10.1 | 161.8 ± 7.4 | 0.40 |
| Body Mass Index (BMI) (mean ± SD) | 23.4 ± 4.3 | 22.6 ± 4.0 | 0.44 |
| Family history of asthma present, n (%) | 13 (44.8) | 11 (39.3) | 0.67 |
| Duration of Asthma, years (mean ± SD) | 11.6 ± 9.5 | 10.5 ± 11.9 | 0.22 |
| Mild asthma, n (%) | 13 (44.8) | 11 (39.3) | 0.78 |
| Moderate asthma, n (%) | 16 (55) | 17 (60.7) | 0.82 |
| FVC (% of predicted) | 78.7 ± 13.3 | 75.2 ± 15.0 | 0.35 |
| FEV1 (% of predicted) | 70.2 ± 17.4 | 62.5 ± 19.2 | 0.11 |
| FEV1/FVC (% of predicted) | 80.4 ± 11.5 | 73.7 ± 14.8 | 0.06 |
| PEFR (% of predicted) | 68.6 ± 18.4 | 57.4 ± 19.7 | |
| FEF25-75 (% of predicted) | 38.4 ± 14.5 | 33.9 ± 18.3 | 0.31 |
| Serum ECP level (ng/mL) | 1.32 ± 0.51 | 1.25 ± 0.43 | 0.89 |
| EIB (%fall in FEV1 with EC) | 15.0 ± 14.0 | 9.1 ± 10.8 | 0.16 |
| Urinary 11β-PGF2α before exercise (pg/mg of creatinine), median (IQR) | 455.4 | 223.7 | 0.12 |
| Δ Urinary 11β-PGF2α (pg/mg of creatinine) with exercise challenge, median (IQR) | 26.9 (7.4–218) | 38.4 (3.1–108) | 0.55 |
| AQOL total score | 3.72 ± 1.17 | 3.64 ± 1.14 | 0.80 |
| AQOL symptoms score | 3.77 ± 1.34 | 3.62 ± 1.42 | 0.70 |
| AQOL activity limitation score | 3.66 ± 1.13 | 3.67 ± 1.17 | 0.95 |
| AQOL emotional function score | 3.94 ± 1.47 | 3.59 ± 1.39 | 0.35 |
| AQOL environmental stimuli score | 3.72 ± 1.17 | 4.04 ± 1.42 | 0.14 |
Abbreviations: AQOL, Asthma Quality of Life; FEV1, forced expiratory volume in 1 second; FEF25–75%, forced mid-expiratory flow between 25% and 75% of FVC; FVC, forced vital capacity; PEFR, peak expiratory flow rate; ECP, eosinophilic cationic protein; IQR, inter- quartile range; EC, exercise challenge; EIB, exercise-induced bronchoconstriction; 11β-PGF2α, 11β prostaglandin F2α.
p-value obtained by from Chi-square analysis or 't' test or Mann-Whitney U test depending on the type of variables.
All values are expressed as mean ± SD, except ECP expressed as log-transformed values and 11β-PGF2α as median with inter-quartile range.
Daily dose of inhaled corticosteroids and rescue medication at baseline
| Mean inhaled steroid dose, μg/day | 320.4 ± 158.8 | 360 ± 151.4 | 0.48 |
| Rescue medication use (puffs/day)¥ | 2.27 ± 1.5 | 1.98 ± 2.09 | 0.19 |
§ Daily dose of inhaled steroids in beclomethasone μg equivalents over the past 1-2 wk.
These were calculated on the assumption that beclomethasone 2000 μg = budesonide 1600 μg = fluticasone 1000 μg.
¥ Rescue medication = Inhaled rescue bronchodilator intake (puffs/day) use per day and an average for 2 weeks preceding the study visit.
p-value obtained from Chi-square analysis or Mann-Whitney U test.
Results of pulmonary function indices during the study
| Yoga | 68.6 ± 18.4 | 76.5 ± 20.5* | 81.5 ± 20.9‡ | 85.3 ± 20.7‡ | 0.000 | |
| Control | 57.4 ± 19.7 | 58.2 ± 22.0 | 56.9 ± 26.2 | 56.2 ± 22.0 | ||
| Yoga | 70.2 ± 17.4 | 73.9 ± 19.6 | 76.1 ± 20.1 | 77.9 ± 17.2* | 0.009 | |
| Control | 62.5 ± 19.2 | 63.1 ± 20.5 | 60.5 ± 21.6 | 59.9 ± 19.1 | ||
| Yoga | 78.7 ± 13.4 | 78.0 ± 12.6 | 79.3 ± 13.0 | 82.2 ± 10.7 | NS | |
| Control | 75.0 ± 15.0 | 74.7 ± 18.3 | 73.4 ± 18.1 | 72.5 ± 17.5 | ||
| Yoga | 80.4 ± 11.5 | 82.6 ± 13.3 | 83.7 ± 13.4 | 83.1 ± 12.2 | 0.011 | |
| Control | 73.7 ± 14.9 | 74.8 ± 13.9 | 72.4 ± 15.1 | 73.3 ± 13.8 | ||
| Yoga | 38.4 ± 14.6 | 42.0 ± 19.4 | 45.0 ± 20.5 | 45.0 ± 19.7 | 0.035 | |
| Control | 34.0 ± 18.3 | 33.8 ± 17.8 | 32.4 ± 18.1 | 31.1 ± 17.1 | ||
All values are % of predicted and expressed as mean ± SD.
* p < .05; † p < .01; ‡ p < .001 based on post-hoc pair wise comparisons with 0 wk values.
p-values were obtained from the between groups comparison in the GLM, NS – not significant
Exercise induced bronchoconstriction during the study
| % fall in FEV1 with exercise challenge | Yoga | 15.05 ± 14.0 | 8.81 ± 12.9 | 5.65 ± 12.9 | 5.18 ± 11.8 | 0.005 |
| Control | 9.13 ± 10.8 | 9.50 ± 11.1 | 10.28 ± 10.9 | 5.81 ± 10.1 | NS | |
| ES subjects | Yoga | 26.71 ± 12.7 | 13.33 ± 16.1 | 9.90 ± 14.5 | 7.95 ± 15.1 | 0.003 |
| Control | 21.47 ± 6.4 | 8.83 ± 9.8 | 18.69* ± 8.2 | 12.71 ± 9.1 | 0.015 | |
| ER subjects | Yoga | 5.58 ± 5.1 | 5.13 ± 8.4 | 2.20 ± 10.6 | 2.93 ± 8.0 | NS |
| Control | 3.29 ± 6.6 | 9.82 ± 11.9 | 6.31 ± 9.8 | 2.53 ± 9.0 | NS | |
All values are expressed as mean ± SD. ES – exercise sensitive; ER – exercise resistant.
P-value was based on Friedman test applied on % fall in FEV1 after exercise challenge within each group separately.
* Between groups comparisons were made by Mann-Whitney U test at individual visits, there was significant difference observed at 4 wk between groups in exercise-sensitive subjects (p = 0.025).
Normalized values of Δ urinary 11β-PGF2α with exercise challenge
| % change in 11β-PGF2α excretion. (All subjects) | Yoga | 17.6 ± 18.6 | 19.7 ± 24.7 | 14.7 ± 16.5 | 16.8 ± 19.7 | 0.49 |
| Control (n = 28) | 16.6 ± 21.0 | 18.6 ± 22.0 | 16.3 ± 22.3 | 20.7 ± 23.5 | 0.84 | |
| ES subjects | Yoga | 18.3 ± 22.2 | 20.4 ± 29.5 | 13.8 ± 16.8 | 12.3 ± 16.9 | 0.63 |
| Control | 15.5 ± 21.2 | 13.3 ± 18.1 | 28.5 ± 16.3* | 18.9 ± 8.2 | 0.11 | |
| ER subjects | Yoga | 17.1 ± 15.9 | 19.0 ± 21.0 | 15.4 ± 16.8 | 20.4 ± 21.5 | 0.79 |
| Control | 17.0 ± 21.5 | 21.1 ± 23.6 | 10.6 ± 22.8 | 21.6 ± 28.2 | 0.08 | |
All values (normalized) are expressed as % change in 11β prostaglandin F2α excretion with exercise challenge (mean ± SD). ES – exercise sensitive; ER – exercise resistant subjects.
aP-value was based on Friedman test in each group separately from % change in 11β-PGF2α with exercise.
*p < .05 based on Mann-Whitney U test at 4 wk between two groups.
Asthma quality of life scores during the study
| Symptoms | Yoga | 3.77 ± 1.3 | 5.07 ± 1.4‡ | 5.38 ± 1.1‡ | 5.42 ± 1.2‡ | 0.033 |
| Control | 3.63 ± 1.4 | 3.96 ± 1.7 | 4.42 ± 1.5† | 4.70 ± 1.7† | ||
| Activity limitation | Yoga | 3.66 ± 1.1 | 4.82 ± 1.3‡ | 5.21 ± 1.0‡ | 5.47 ± 1.1‡ | 0.033 |
| Control | 3.67 ± 1.2 | 3.74 ± 1.5 | 3.90 ± 1.4 | 4.20 ± 1.5 | ||
| Emotional function | Yoga | 3.94 ± 1.5 | 5.10 ± 1.6† | 5.45 ± 1.3‡ | 5.71 ± 1.3‡ | 0.006 |
| Control | 3.60 ± 1.4 | 4.01 ± 1.6 | 4.15 ± 1.8 | 4.32 ± 1.7 | ||
| Response to environmental stimuli | Yoga | 3.46 ± 1.5 | 4.64 ± 1.5‡ | 5.0 ± 1.4‡ | 5.3 ± 1.6‡ | NS |
| Control | 4.04 ± 1.4 | 3.83 ± 1.5 | 4.08 ± 1.6 | 4.40 ± 1.8 | ||
| Total Quality of Life | Yoga | 3.72 ± 1.2 | 4.93 ± 1.3‡ | 5.28 ± 1.0‡ | 5.46 ± 1.1‡ | 0.013 |
| Control | 3.64 ± 1.1 | 3.90 ± 1.5 | 4.17 ± 1.4* | 4.50 ± 1.5† | ||
All values are expressed as mean ± SD.
* p < .05; † p < .01; ‡ p < .001 based on post-hoc pair wise comparisons with 0 wk values.
p-values were obtained from the between groups comparison in the GLM, NS – not significant.
Figure 1Serum eosinophilic cationic protein in yoga group during the study. Serum eosinophilic cationic protein in yoga group (n = 29) during 8 wk study period. Horizontal thick bars indicate median values and box the interquartile range (IQR).
Figure 2Serum eosinophilic cationic protein in control group during the study. Serum eosinophilic cationic protein in control group (n = 28) during 8 wk study period
Figure 3Frequency of rescue medication use in yoga and control groups. Rescue medication use was calculated as an average use of short acting β2-agonists per day (puffs/day) for 2 wk, hence, there are five time points. There is significant overall decline in rescue medication use in both yoga (p < .001) and control groups (p < .05). Also significant differences seen at 2 wk (p < .05) and 4 wk (p < .01) between yoga and control groups.